Descartes-08

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myasthenia Gravis, Generalized

Conditions

Myasthenia Gravis, Generalized

Trial Timeline

Dec 4, 2019 → Mar 31, 2026

NCT ID

NCT04146051

About Descartes-08

Descartes-08 is a phase 2 stage product being developed by Cartesian Therapeutics for Myasthenia Gravis, Generalized. The current trial status is active. This product is registered under clinical trial identifier NCT04146051. Target conditions include Myasthenia Gravis, Generalized.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis, Generalized were approved

Approved (1) Terminated (2) Active (17)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄tacrolimus + placeboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07391605	Phase 2	Recruiting	Mar 1, 2026	May 1, 2027	Antisynthetase Syndrome
NCT07089121	Phase 1/2	Recruiting	Jan 1, 2026	Dec 1, 2026	Childhood-onset Systemic Lupus Erythematous
NCT06038474	Phase 2	Active	Feb 12, 2024	Nov 1, 2026	Systemic Lupus Erythematosus (SLE)
NCT04146051	Phase 2	Active	Dec 4, 2019	Mar 31, 2026	Myasthenia Gravis, Generalized

Competing Products

20 competing products in Myasthenia Gravis, Generalized

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44